

## CURRICULUM VITAE DI TRAVELLI CRISTINA



### PERSONAL INFORMATION

Name: Cristina Travelli  
Citizenship: Italian  
E-mail: cristina.travelli@unipv.it  
Spoken Languages: English (C2), French (B2), German (A1)

### WORKING INFORMATION

University: University of Pavia  
Department: Department of Pharmaceutical Sciences  
Address: viale Taramelli 12, 27100, Pavia, ITALY  
Telephone/fax: 0039 0382 987402  
Scopus ID: 23989511500

### ACADEMIC CAREER

**2018:** National habilitation in Pharmacology

**2009-2013:** Ph.D. in Food and Drug Biotechnologies at “Università del Piemonte Orientale” (UPO)

**2007-2009:** Master’s Degree in Medical and Pharmaceutical Biotechnologies at “Università del Piemonte Orientale” (UPO)

**2004-2007:** Bachelor’s Degree in Biotechnologies at “Università del Piemonte Orientale” (UPO)

### PROFESSIONAL EXPERIENCE

**2022-present:** Associate professor In Pharmacology, at University of Pavia, Italy. “Corso di Metodologie preclinica e clinica” e “Laboratorio di Farmacologia Sperimentale”, III anno CTF.

**2019-2021:** Tenure Track Professor (Ricercatore a tempo determinato-tipologia B; RTD-B) at University of Pavia, Italy.

Research area: study of novel therapeutic agents in inflammatory disorders and breast cancer.

**2018-2019:** Contract Professor of Pharmacology at Università del Piemonte Orientale in the Biotechnology bachelor degree.

**2018:** Umberto Veronesi Fellow at Department of Pharmaceutical Sciences DSF, Novara, Italy.

Research area: Targeting eNAMPT in triple negative breast cancer

**2017-2018:** Teaching assistant (Cultore della Materia) in Pharmacology, (UPO), Novara, Italy.

**2016-present:** collaboration with Dr. Rita De Sanctis, Cancer Center, Istituto Clinico Humanitas

Protocol approved: Immuno-metabolomic profiling of Soft Tissue Sarcomas and Breast Cancer  
**2016-2018:** Post-Doc position in the Lab of Prof. Armando Genazzani, Department of Pharmaceutical Sciences DSF, Novara, Italy.  
Research area: Targeting eNAMPT in inflammatory-bowel disease (IBD)  
**2015-present:** collaboration with Prof. Mario Paolo Colombo, Istituto Nazionale Tumori, Milano, Italy.  
Research area: role of NAMPT in myelopoiesis  
**2014- present:** collaboration with Prof. Fabio Malavasi in Laboratory of Immunogenetics, University of Torino, Italy.  
Research area: Generation and characterization of eNAMPT monoclonal antibodies  
**2013-2016:** FIRC fellowship at Department of Pharmaceutical Sciences DSF, Novara, Italy.  
Research area: Intra- and Extra-cellular NAMPT in myeloid-derived suppressor cells  
**2011-2012:** experience in the Lab of Prof. Antonio Sica, Istituto Clinico Humanitas (ICH), Rozzano, Italy.  
Research area: characterization of the role of NAMPT and NAD metabolism in immune cells in cancer  
**2009-2013:** experience in the Lab of Prof. Armando Genazzani, DSF, Novara, Italy.  
Research area: Targeting Nicotinamide Phosphoribosyltransferase (NAMPT) in cancer Therapy  
**2006-2009:** experience in the Lab of Prof. Armando Genazzani, DSF, Novara, Italy.  
Research area: NAD metabolism and characterization of NAMPT inhibitors as autophagy Inducers  
Career Breaks: none

## **HONOURS and AWARDS**

**2019:** FONDAZIONE UMBERTO VERONESI: 1 -year Post-Doctoral fellowship in Oncology (**27000€**), declined  
**2018:** FONDAZIONE UMBERTO VERONESI: 1 -year Post-Doctoral fellowship in Oncology (**27000€**)  
**2017:** Travel Grant: "Brainstorming Meeting on CD38 and CD157", San Benedetto PO- Mantova (**500€**)  
**2017:** Gianfranco Ferro Fellowship-SIF, Title: "TARGETING EXTRACELLULAR NICOTAMIDE PHOSPHORIBOSYL TRANSFERASE (eNAMPT) IN BREAST CANCER" (**10000 €**), declined  
**2015:** AACR-Travel Grant: American Association for Cancer Research (AACR)-Pezcoller Foundation Scholar-In-Training Award Travel, Philadelphia, (**1500\$**)  
**2013-2016:** 3 years AIRC-FIRC fellowship "Leonino Fontana e Maria Lionello" (**70000€**)  
**2013:** Prize SIF-TAKEDA from "Società Italiana di Farmacologia (SIF)" and Takeda for the best project in Onco-Pharmacology (**12500 €**)  
**2013:** Prize SIF per best oral communication, Antineoplastic Drugs at 36<sup>^</sup> Congresso nazionale della Società Italiana di Farmacologia (SIF) 2013 (**500€**)

## **LEARNED SOCIETIES AND BOARDS**

Learned Societies and Boards

**SIF** - Società Italiana di Farmacologia

**ECCO**- European Crohn's and Colitis Organisation

**AACR**- American Association for Cancer Research

## **EDITORIAL ACTIVITIES**

**2023:** Farmacologia Seconda edizione Casa Editrice Ambrosiana. Distribuzione esclusiva Zanichelli  
2023

**2023-now:** Chief Editor Inflammation Pharmacology section, "Women in Inflammation Pharmacology: 2023"

**2020-now:** Biology guest editor, MDPI, "Inflammation in cancer: a target for prevention and therapy" edition I

**2020-present:** Reviewer Board of Frontiers in Immunology

#### **FUNDING PI and CO-PI**

**2023: PRIN 2022-PNRR:** P2022JW2BE Deciphering the role of the cytokine eNAMPT in controlling neuroinflammation in Parkinson Diseases (CO-PI)

**2023: PRIN 2022 2022F7K7RY** Bitter taste receptors in Inflammatory Bowel Diseases: possible new drug targets

**2023: IMMUNO-HUB:** IMMUNOTERAPIA: CURA E PREVENZIONE DI MALATTIE INFETTIVE E TUMORALI

**2022:** Co-Pi in **GR-2021** "Study of the role of the extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in the pathogenic networks underlying psoriasis and the comorbid condition of obesity" (

**2022: Centro Nazionale-CN3**\_partecipante CN\_00000041; CENTRO NAZIONALE SULLO SVILUPPO DI TERAPIA GENICA E FARMACI CON TECNOLOGIA A RNA\_SPOKE 9

**2020: PRIN2020**\_Regulation of autophagy by N-acylethanolamines as a promising approach for the treatment of inflammatory-based diseases: from neurodegeneration to metabolic disorders

**2020: Bando Cariplo 2020**\_Bando Cariplo Giovani ricercatori: PI of the project "Extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT): role in the pathogenesis and progression of Inflammatory Bowel Diseases"

**Angelini SPA-2017-2019:** PI in the study of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors funded by ANGELINI S.p.A. Contract title: "Studi di farmacocinetica, efficacia e di safety dei lead MV87, MS33 a MD65".

#### **FUNDING co applicant**

**AIRC- 2018:** co-applicant with Prof. Genazzani. Title project: "Extracellular NAMPT in breast cancer: roles and evaluation of the therapeutic potential of its neutralization", AIRC.

**PRIN-2015:** co-applicant with Prof. Genazzani. Title Project "Attività antinfiammatoria dei Glucocorticoidi: nuovi mediatori e regolazione dell'attività dei linfociti T". PI: Carlo Riccardi

**AIRC-2013:** co-applicant with Prof. Genazzani. Title project: "The NAD salvage Pathway as a therapeutic target in melanoma", AIRC IG10509

**Compagnia San Paolo- 2012:** co-applicant with Prof. Genazzani at oncoNAMPT-Compagnia San Paolo (CUP: C61J12000280007) project: "Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as Potential Chemotherapeutic Agents (oncoNAMPT)".

#### **PATENT, SPIN OFF E START UP**

**PATENT-2014:** International patent PCT/IB2014/061080- WO2014178001, "Inhibitors of Nicotinamide Phosphoribosyltransferase, compositions, products and use thereof".

**Total number of referred publications, H index, Number of citations**

**40** publications  
Citations: **1579**  
H-index: **22**